Great questions -The first line of defense against interstitial fluid is wiping away the first drop (commonly used protocol in most drop test). The inevitable

Great questions -The first line of defense against interstitial fluid is wiping away the first drop (commonly used protocol in most drop test). The inevitable remaining interstitial fluid chunk is then classified out by our image processing models, which have been trained to recognize differences in images based on debris/cell concentration. -We currently report the WBC, WBC Differential, Platelets, and RBC indices. The flags we're missing are secondary RBC metrics like MCH and RDW estimates but we have plans to roll these out soon as well. -Yes, we've run both bench and clinical testing on patients with north of 100k white blood cells - the image processing can segment out cell chunks in these crowded samples better than traditional flow cytometry. Not in the currently published studies, but some good data coming out about this soon. -We've run basic initial tests on platelet clumping (artificially induced in certain diluted samples), and present in clinical samples. Since our model looks at the boundaries of these platelet cells, we have a lot less trouble with this than flow cytometry/beckman and even human pathologists. Still, we're working to find more samples with clumping to define the limits of detection on this front. -We've done interference studies with Hemolysis, EDTA, not with lipemia and icetrus. These are on our list of clinical samples to source as well. -We've begun working with some of these EMR providers, the good thing is many of them have sandboxes to get setup in relatively quickly. The larger ones do have long, long-term engagement timelines. -We work with dozens of pathologists to help review results, train the system further, and in general go over good morphology practice. Has definitely been a core part of our strategy.